Richard Arnold
Endocrinology, Diabetes & Metabolism · New York, NYNPI 1750300380
Payments from drug & device makers
Across 360 payments — averaging $23.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$2K
- Lilly USA, LLC$2K
- Novo Nordisk$870
- Intra-sana Laboratories$761
- AstraZeneca$677
- Xeris Pharmaceuticals, Inc.$445
- plus $2K from 21 others
What the payments were for
- Food & beverage$8,33299%
- Education$531%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen(2 entities) | 36 | $1,608 |
| Lilly USA, LLC | 115 | $1,580 |
| Novo Nordisk | 47 | $870 |
| Intra-sana Laboratories | 10 | $761 |
| AstraZeneca | 35 | $677 |
| Xeris Pharmaceuticals, Inc. | 6 | $445 |
| Idorsia Pharmaceuticals US Inc | 21 | $377 |
| AbbVie(2 entities) | 15 | $321 |
| Bayer | 11 | $312 |
| BETA Bionics, Inc. | 4 | $304 |
| Merck | 13 | $207 |
| Corcept Therapeutics | 3 | $201 |
| Abbott | 14 | $128 |
| Sanofi-aventis U.S. LLC | 4 | $100 |
| Amarin Pharma, Inc. | 5 | $89 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 3 | $53 |
| Insulet Corporation | 2 | $51 |
| Radius Health, Inc. | 2 | $47 |
| Ironwood Pharmaceuticals, Inc | 2 | $41 |
| Ultragenyx Pharmaceutical Inc. | 2 | $41 |
| Mannkind Corporation | 2 | $35 |
| Antares Pharma, Inc. | 2 | $32 |
| IBSA Pharma Inc. | 2 | $29 |
| Kyowa Kirin, Inc. | 1 | $21 |
| Amneal Pharmaceuticals LLC | 1 | $20 |
| Endo Pharmaceuticals Inc. | 1 | $19 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- TEPEZZA$911
- iLet Bionic Pancreas$819
- Reltone 200 Mg$620
- GLYCATE$620
- Reltone 400 Mg$620
- iLet Insulin Infusion Kit Inset$273
- iLet Insulin Infusion Kit Contact Detach$273
- RECORLEV$260
- EVENITY$233
- GVOKE HYPOPEN$150
- LINZESS$125
- RYBELSUS$125
- Korlym$125
- QUVIVIQ$125
- MOUNJARO$122
- Kerendia$120
How this compares
$8,385 in reported general payments places this provider in the 75th percentile of 804 endocrinology, diabetes & metabolism providers in New York.
See all endocrinology, diabetes & metabolism providers in New York →
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| GenvoyaElviteg/Cob/Emtri/Tenof Alafen | 11 | $43,090 |
| OzempicSemaglutide | 15 | $16,516 |
| JardianceEmpagliflozin | 12 | $15,598 |
| KerendiaFinerenone | 11 | $13,674 |
| SynthroidLevothyroxine Sodium | 20 | $2,383 |
| Olmesartan Medoxomil | 23 | $666 |
| Rosuvastatin Calcium | 26 | $499 |
| Metformin Hcl ErMetformin Hcl | 18 | $355 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 12 | $159 |
| Amlodipine Besylate | 23 | $100 |
| Minoxidil | 11 | $51 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $870 | $16,51615 claims |
| BayerKerendia | $312 | $13,67411 claims |
| AbbVieSynthroid | $321 | $2,38320 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 804 endocrinology, diabetes & metabolism providers in New York.
Other endocrinology, diabetes & metabolism in New York
- Anastasios ManessisNew York$4.4M
- Adi CohenNew York$2.5M
- Carol LevyNew York$2.2M
- Mishaela RubinNew York$2M
- Henry GinsbergNew York$1M
- John BilezikianNew York$814K
- Eliza GeerNew York$760K
- Christoph BuettnerNew York$709K
- Emily SteinNew York$489K
- Jason BakerNew York$489K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.